Treatment of cutaneous leishmaniasis among travellers

Journal of Antimicrobial Chemotherapy

Volumn 53, Issue 2, 2004, Pages 158-166

  Blum, Johannes ^a   Desjeux, P ^b   Schwartz, E ^c,d   Beck, B ^a   Hatz, C ^a  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c SHEBA MEDICAL CENTER   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

Cutaneous leishmaniasis; Local treatment; Systemic treatment; Travel

Indexed keywords

ALLOPURINOL; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; BENZETHONIUM CHLORIDE; DAPSONE; FLUCONAZOLE; ISOENZYME; ITRACONAZOLE; KETOCONAZOLE; MEGLUMINE ANTIMONATE; MILTEFOSINE; PAROMOMYCIN; PENTAMIDINE; PLACEBO; POTASSIUM; RIFAMPICIN; STIBOGLUCONATE SODIUM; UREA; ZINC SULFATE;

ABDOMINAL PAIN; ABSCESS; ACUTE KIDNEY FAILURE; ANEMIA; ANTIBIOTIC RESISTANCE; BLOOD CULTURE; CAUTERIZATION; CRYOTHERAPY; DIABETES MELLITUS; DISEASE COURSE; DISEASE SEVERITY; ENZYME ANALYSIS; EXFOLIATIVE DERMATITIS; FEVER; GASTROINTESTINAL DISEASE; GEOGRAPHICAL VARIATION (SPECIES); GLOMERULONEPHRITIS; HEADACHE; HEART ARRHYTHMIA; HEART MUSCLE CONDUCTION DISTURBANCE; HERPES ZOSTER; HUMAN; HYPERTHERMIC THERAPY; HYPOGLYCEMIA; HYPOKALEMIA; HYPOTENSION; KIDNEY TUBULE DISORDER; LEISHMANIA; LEISHMANIA BRAZILIENSIS; LEISHMANIA DONOVANI; LEISHMANIA MEXICANA; LEISHMANIA PANAMENSIS; LEUKOPENIA; LIBIDO DISORDER; LIVER DISEASE; MALAISE; MEDICAL DECISION MAKING; MOTION SICKNESS; MUSCULOSKELETAL DISEASE; NAUSEA; POLYMERASE CHAIN REACTION; PROTEINURIA; REVIEW; SKIN DISEASE; SKIN LEISHMANIASIS; SKIN SURGERY; SPECIES DIFFERENCE; SPECIES IDENTIFICATION; TASTE DISORDER; THROMBOCYTOPENIA; THROMBOPHLEBITIS; TRAVEL; TREATMENT INDICATION; TREATMENT OUTCOME; UREMIA; VARICELLA ZOSTER VIRUS;

ADMINISTRATION, TOPICAL; ANIMALS; ANTIMONY; ANTIPROTOZOAL AGENTS; HUMANS; LEISHMANIASIS, CUTANEOUS; TRAVEL; TREATMENT FAILURE;

EID: 1242307777     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh058     Document Type: Review

References (84)

1. Ballou, W. R., McClain, J. B., Gordon, D. M. et al. (1987). Safety and efficacy of high-dose sodium stibogluconate therapy of American cutaneous leishmaniasis. Lancet ii, 13-6.
2. Wortmann, G., Miller, R. S., Oster, C. et al. (2002). A randomized, double-blind study of the efficacy of a 10- or 20-day course of sodium stibogluconate for treatment of cutaneous leishmaniasis in United States military personnel. Clinical Infectious Diseases 35, 261-7.
3. Aronson, N. E., Wortmann, G. W., Johnson, S. C. et al. (1998). Safety and efficacy of intravenous sodium stibogluconate in the treatment of leishmaniasis: recent U.S. military experience. Clinical Infectious Diseases 27, 1457-64.
4. Gutierrez, Y., Salinas, G. H., Palma, G. et al. (1991). Correlation between histopathology, immune response, clinical presentation, and evolution in Leishmania braziliensis infection. American Journal of Tropical Medicine and Hygiene 45, 281-9.
5. Palacios, R., Osorio, L. E., Grajalew, L. F. et al. (2001). Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimonate for cutaneous leishmaniasis due to Leishmania viannia species. American Journal of Tropical Medicine and Hygiene 64, 187-93.
6. Nacher, M., Carme, B., Sainte, M. D. et al. (2001). Influence of clinical presentation on the efficacy of a short course of pentamidine in the treatment of cutaneous leishmaniasis in French Guiana. Annals of Tropical Medicine and Parasitology 95, 331-6.
7. Desjeux, P. (2001). Worldwide increasing risk factors for leishmaniasis. Medical Microbiology and Immunology 190, 77-9.
8. Blum, J., Hatz, C. & Junghanss, T. (1994). The therapy of cutaneous and mucocutaneous leishmaniasis. Deutsche Medizinische Wochenschrift 119, 1169-72.
9. Marfurt, J., Niederweiser, I., Makia, N. D. et al. (2003). Diagnostic genotyping of Old and New World Leishmania species by PCR-RFLP. Diagnostic Microbiology and Infectious Disease 46, 115-24.
10. Osorio, L. E., Castillo, C. M. & Ochoa, M. T. (1998). Mucosal leishmaniasis due to Leishmania (Viannia) panamensis in Colombia: clinical characteristics. American Journal of Tropical Medicine and Hygiene 59, 49-52.
11. Saenz, R. E., Paz, H. M., de Rodriguez, G. C. et al. (1989). Mucocutaneous leishmaniasis in Panama. Etiologic agent, epidemiologic and clinical aspects. Revista Medica de Panama 14, 6-15.
12. Santrich, C., Segura, I., Arias, A. L. et al. (1990). Mucosal disease caused by Leishmania braziliensis guyanensis. American Journal of Tropical Medicine and Hygiene 42, 51-5.
13. Lucas, C. M., Franke, E. D., Cachay, M. I. et al. (1998). Geographic distribution and clinical description of leishmaniasis cases in Peru. American Journal of Tropical Medicine and Hygiene 59, 312-7.
14. Saravia, N. G., Segura, I., Holguin, A. F. et al. (1998). Epidemiologic, genetic, and clinical associations among phenotypically distinct populations of Leishmania (Viannia) in Colombia. American Journal of Tropical Medicine and Hygiene 59, 86-94.
15. Marsden, P. D. (1986). Mucosal leishmaniasis ('espundia' Escomel, 1911). Transactions of the Royal Society of Tropical Medicine and Hygiene 80, 859-76.
16. Jones, T. C., Johnson, W. D., Jr, Barretto, A. C. et al. (1987). Epidemiology of American cutaneous leishmaniasis due to Leishmania braziliensis braziliensis. Journal of Infectious Diseases 156, 73-83.
17. Andrade-Narvaez, F. J., Vargas-Gonzalez, A., Canto-Lara, S. B. et al. (2001). Clinical picture of cutaneous leishmaniases due to Leishmania (Leishmania) mexicana in the Yucatan peninsula, Mexico. Memorias do Instituto Oswaldo Cruz 96, 163-7.
18. Blum, J., Junghanss, T. & Hatz, C. (1994). Erroneous tracks in the diagnosis of cutaneous and mucocutaneous leishmaniasis. Schweizerische Rundschau fur Medizin Praxis 83, 1025-9.
19. El Hassan, A. M. & Zijlstra, E. E. (2001). Leishmaniasis in Sudan. Mucosal leishmaniasis. Transactions of the Royal Society of Tropical Medicine and Hygiene 95, Suppl. 1, S19-26.
20. Oliveira-Neto, M. P., Schubach, A., Mattos, M. et al. (1997). Intralesional therapy of American cutaneous leishmaniasis with pentavalent antimony in Rio de Janeiro, Brazil - an area of Leishmania (V.) braziliensis transmission. International Journal of Dermatology 36, 463-8.
21. Seaton, R. A., Morrison, J., Man, I. et al. (1999). Out-patient parenteral antimicrobial therapy - a viable option for the management of cutaneous leishmaniasis. Quarterly Journal of Medicine 92, 659-67.
22. Herwaldt, B. L. & Berman, J. D. (1992). Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. American Journal of Tropical Medicine and Hygiene 46, 296-306.
23. Oliveira-Neto, M. P., Schubach, A., Mattos, M. et al. (1997). A low-dose antimony treatment in 159 patients with American cutaneous leishmaniasis: extensive follow-up studies (up to 10 years). American Journal of Tropical Medicine and Hygiene 57, 651-5.
24. Oliveira-Neto, M. P., Schubach, A., Mattos, M. et al. (1997). Treatment of American cutaneous leishmaniasis: a comparison between low dosage (5 mg/kg/day) and high dosage (20 mg/kg/day) antimony regimens. Pathologie Biologie 45, 496-9.
25. Pradinaud, R. (1994). Le traitement de la leishmaniose tégumentaire par la pentamidine en Guyane française. Medecine Tropicale 54, 418-22.
26. Soto-Mancipe, J., Grogl, M. & Berman, J. D. (1993). Evaluation of pentamidine for the treatment of cutaneous leishmaniasis in Colombia. Clinical Infectious Diseases 16, 417-25.
27. Soto, J., Buffet, P., Grogl, M. et al. (1994). Successful treatment of Colombian cutaneous leishmaniasis with four injections of pentamidine. American Journal of Tropical Medicine and Hygiene 50, 107-11.
28. Amato, V., Amato, J., Nicodemo, A. et al. (1998). Treatment of mucocutaneous leishmaniasis with pentamidine isothionate. Annales de Dermatologie et de Venereologie 125, 492-5.
29. Tomkins, A. & Bryceson, A. (1972). Ocular leishmaniasis and pentamidine diabetes. Transactions of the Royal Society of Tropical Medicine and Hygiene 66, 948-50.
30. Alrajhi, A. A., Ibrahim, E. A., De Vol, E. B. et al. (2002). Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. New England Journal of Medicine 346, 891-5.
31. Soto, J., Toledo, J., Gutierrez, P. et al. (2001). Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clinical Infectious Diseases 33, E57-61.
32. Saenz, R. E., Paz, H. M., Johnson, C. M. et al. (1989). Treatment of American cutaneous leishmaniasis with orally administered allopurinol riboside. Journal of Infectious Diseases 160, 153-8.
33. Guderian, R. H., Chico, M. E., Rogers, M. D. et al. (1991). Placebo controlled treatment of Ecuadorian cutaneous leishmaniasis. American Journal of Tropical Medicine and Hygiene 45, 92-7.
34. Esfandiarpour, I. & Alavi, A. (2002). Evaluating the efficacy of allopurinol and meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis. International Journal of Dermatology 41, 521-4.
35. D'Oliveira, J. A., Machado, P. R. & Carvalho, E. M. (1997). Evaluating the efficacy of allopurinol for the treatment of cutaneous leishmaniasis. International Journal of Dermatology 36, 938-40.
36. Martinez, S. & Marr, J. J. (1992). Allopurinol in the treatment of American cutaneous leishmaniasis. New England Journal of Medicine 326, 741-4.
37. Martinez, S., Gonzalez, M. & Vernaza, M. E. (1997). Treatment of cutaneous leishmaniasis with allopurinol and stibogluconate. Clinical Infectious Diseases 24, 165-9.
38. Kochar, D. K., Aseri, S., Sharma, B. V. et al. (2000). The role of rifampicin in the management of cutaneous leishmaniasis. Quarterly Journal of Medicine 93, 733-7.
39. Dogra, J. (1991). A double-blind study on the efficacy of oral dapsone in cutaneous leishmaniasis. Transactions of the Royal Society of Tropical Medicine and Hygiene 85, 212-3.
40. Sharquie, K. E., Najim, R. A., Farjou, I. B. et al. (2001). Oral zinc sulphate in the treatment of acute cutaneous leishmaniasis. Clinical and Experimental Dermatology 26, 21-6.
41. Bassiouny, A., El Meshad, M., Talaat, M. et al. (1982). Cryosurgery in cutaneous leishmaniasis. British Journal of Dermatology 107, 467-74.
42. Leibovici, V. & Aram, H. (1986). Cryotherapy in acute cutaneous leishmaniasis. International Journal of Dermatology 25, 473-5.
43. al Majali, O., Routh, H. B., Abuloham, O. et al. (1997). A 2-year study of liquid nitrogen therapy in cutaneous leishmaniasis. International Journal of Dermatology 36, 460-2.
44. Gurei, M. S., Tatli, N., Ozbilge, H. et al. (2000). Efficacy of cryotherapy and intralesional pentostam in treatment of cutaneous leishmaniasis. Journal of the Egyptian Society of Parasitology 30, 169-76.
45. Junaid, A. J. (1986). Treatment of cutaneous leishmaniasis with infrared heat. International Journal of Dermatology 25, 470-2.
46. Bryceson, A. D., Murphy, A. & Moody, A. H. (1994). Treatment of 'Old World' cutaneous leishmaniasis with aminosidine ointment: results of an open study in London. Transactions of the Royal Society of Tropical Medicine and Hygiene 88, 226-8.
47. Arana, B. A., Mendoza, C. E., Rizzo, N. R. et al. (2001). Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala. American Journal of Tropical Medicine and Hygiene 65, 466-70.
48. Krause, G. & Kroeger, A. (1994). Topical treatment of American cutaneous leishmaniasis with paramomycin and methylbenzethonium chloride: a clinical study under field conditions in Ecuador. Transactions of the Royal Society of Tropical Medicine and Hygiene 88, 92-4.
49. Munir, M., Mohammed, K. & Babkerhyl, M. (2002). Guidelines for the Treatment and Prevention of Cutaneous Leishmaniasis in Pakistan. Ministry of Health Pakistan; WHO, Health Net International.
50. Berman, J. D. (1997). Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clinical Infectious Diseases 24, 684-703.
51. el On, J., Cawich, F., Evans, D. A. et al. (1993). Topical treatment of cutaneous leishmaniasis in Belize: in vitro and in vivo studies with Leishmania mexicana. International Journal for Parasitology 23, 121-7.
52. Weinrauch, L., Cawich, F, Craig, P. et al. (1993). Topical treatment of New World cutaneous leishmaniasis in Belize: a clinical study. Journal of the American Academy of Dermatology 29, 443-6.
53. Navin, T. R., Arana, B. A., Arana, F. E. et al. (1992). Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. Journal of Infectious Diseases 165, 528-34.
54. Saenz, R. E., Paz, H. & Berman, J. D. (1990). Efficacy of ketoconazole against Leishmania braziliensis panamensis cutaneous leishmaniasis. American Journal of Medicine 89, 147-55.
55. Soto, J., Fuya, P., Herrera, R. et al. (1998). Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: controlled study. Clinical Infectious Diseases 26, 56-8.
56. Llanos-Cuentas, A., Echevarria, J., Cruz, M. et al. (1997). Efficacy of sodium stibogluconate alone and in combination with allopurinol for treatment of mucocutaneous leishmaniasis. Clinical Infectious Diseases 25, 677-84.
57. Romero, G. A., Guerra, M. V., Paes, M. G. et al. (2001). Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: therapeutic response to meglumine anti-moniate. American Journal of Tropical Medicine and Hygiene 65, 456-65.
58. Herwaldt, B. L. (1999). Leishmaniasis. Lancet 354, 1191-9.
59. Almeida, R., D'Oliveira, A., Jr, Machado, P. et al. (1999). Randomized, double-blind study of stibogluconate plus human granulocyte macrophage colony-stimulating factor versus stibogluconate alone in the treatment of cutaneous leishmaniasis. Journal of Infectious Diseases 180, 1735-7.
60. Navin, T. R., Arana, B. A., Arana, F. E. et al. (1990). Placebo-controlled clinical trial of meglumine antimonate (glucantime) vs. localized controlled heat in the treatment of cutaneous leishmaniasis in Guatemala. American Journal of Tropical Medicine and Hygiene 42, 43-50.
61. el On, J., Halevy, S., Grunwald, M. H. et al. (1992). Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major. a double-blind control study. Journal of the American Academy of Dermatology 27, 227-31.
62. el On, J., Livshin, R., Paz, Z. E. et al. (1985). Topical treatment of cutaneous leishmaniasis. Journal of Investigative Dermatology 291, 1280-1.
63. Asilian, A., Jalayer, T., Whitworth, J. A. et al. (1995). A randomized, placebo-controlled trial of a two-week regimen of aminosidine (paromomycin) ointment for treatment of cutaneous leishmaniasis in Iran. American Journal of Tropical Medicine and Hygiene 53, 648-51.
64. Ben Salah, A., Zakraoui, H., Zaatour, A. et al. (1995). A randomized, placebo-controlled trial in Tunisia treating cutaneous leishmaniasis with paromomycin ointment. American Journal of Tropical Medicine and Hygiene 53, 162-6.
65. Alkhawajah, A. M., Larbi, E., al Gindan, Y. et al. (1997). Treatment of cutaneous leishmaniasis with antimony: intramuscular versus intralesional administration. Annals of Tropical Medicine and Parasitology 91, 899-905.
66. Faris, R. M., Jarallah, J. S., Khoja, T. A. et al. (1993). Intralesional treatment of cutaneous leishmaniasis with sodium stibogluconate antimony. International Journal of Dermatology 32, 610-2.
67. Tallab, T. M., Bahamdam, K. A., Mirdad, S. et al. (1996). Cutaneous leishmaniasis: schedules for intralesional treatment with sodium stibogluconate. International Journal of Dermatology 35, 594-7.
68. Weinrauch, L., Livshin, R. & el On, J. (1987). Ketoconazole in cutaneous leishmaniasis. British Journal of Dermatology 117, 666-8.
69. Weinrauch, L., Livshin, R., Even-Paz, Z. et al. (1983). Efficacy of ketoconazole in cutaneous leishmaniasis. Archives of Dermatological Research 275, 353-4.
70. Anders, G., Eisenberger, C. L., Jonas, F. et al. (2002). Distinguishing Leishmania tropica and Leishmania major in the Middle East using the polymerase chain reaction with kinetoplast DNA-specific primers. Transactions of the Royal Society of Tropical Medicine and Hygiene 96, Suppl. 1, S87-92.
71. Singh, S., Singh, R. & Sundar, S. (1995). Failure of ketoconazole in oriental sore in India. Journal of Chemotherapy 7, Suppl. 4, 202-3.
72. Singh, S., Singh, R. & Sundar, S. (1995). Failure of ketoconazole treatment in cutaneous leishmaniasis. International Journal of Dermatology 34, 120-1.
73. Del Giudice, P., Marty, P., Lacour, J. P. et al. (1998). Cutaneous leishmaniasis due to Leishmania infantum. Case reports and literature review. Archives of Dermatology 134, 193-8.
74. Scope, A., Trau, H., Andreas, G. et al. (2003). Experience with New World cutaneous leishmaniasis in Israeli travelers. Journal of the American Academy of Dermatology 49, 672-8.
75. Schubach, A., Haddad, F., Oliveira-Neto, M. P. et al. (1998). Detection of Leishmania DNA by polymerase chain reaction in scars of treated human patients. Journal of Infectious Diseases 178, 911-4.
76. Antezana, G., Zeballos, R., Mendoza, C. et al. (1992). Electrocardiographic alterations during treatment of mucocutaneous leishmaniasis with meglumine antimoniate and allopurinol. Transactions of the Royal Society of Tropical Medicine and Hygiene 86, 31-3.
77. Ribeiro, A. L., Drummond, J. B., Volpini, A. C. et al. (1999). Electrocardiographic changes during low-dose, short-term therapy of cutaneous leishmaniasis with the pentavalent antimonial meglumine. Brazilian Journal of Medical and Biological Research 32, 297-301.
78. Hepburn, N. C., Siddique, I., Howie, A. F. et al. (1993). Hepato-toxicity of sodium stibogluconate in leishmaniasis. Lancet 342, 238-9.
79. Hepburn, N. C. (1993). Thrombocytopenia complicating sodium stibogluconate therapy for cutaneous leishmaniasis. Transactions of the Royal Society of Tropical Medicine and Hygiene 87, 691.
80. Gasser, R. A., Jr, Magill, A. J., Oster, C. N. et al. (1994). Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis. Clinical Infectious Diseases 18, 83-90.
81. Rodrigues, M. L., Costa, R. S., Souza, C. S. et al. (1999). Nephrotoxicity attributed to meglumine antimoniate (Glucantime) in the treatment of generalized cutaneous leishmaniasis. Revista do Instituto de Medicina Tropical de Sao Paulo 41, 33-7.
82. Brummitt, C. F., Porter, J. A. & Herwaldt, B. L. (1996). Reversible peripheral neuropathy associated with sodium stibogluconate therapy for American cutaneous leishmaniasis. Clinical Infectious Diseases 22, 878-9.
83. Wortmann, G. W., Aronson, N. E., Byrd, J. C. et al. (1998). Herpes zoster and lymphopenia associated with sodium stibogluconate therapy for cutaneous leishmaniasis. Clinical Infectious Diseases 27, 509-12.
84. Hellier, I., Dereure, O., Tournillac, I. et al. (2000). Treatment of Old World cutaneous leishmaniasis by pentamidine isethionate. An open study of 11 patients. Dermatology 200, 120-3.